Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others


Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma

Badri Nabeel, Ngamdu Kyari Sumayin, Torabi Alireza, Guar Sumit

Year : 2020| Volume: 16| Issue : 1 | Page no: 183-185

   This article has been cited by
1 CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies
Roland Schwarting, Eric Behling, Ashleigh Allen, Vivian Arguello-Guerra, Tulin Budak-Alpdogan
Archives of Pathology & Laboratory Medicine. 2022; 146(4): 415
[Pubmed]  [Google Scholar] [DOI]
2 Treatment of Primary Mediastinal B-Cell Lymphoma With R-CEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, and Prednisone)
Sundar V Cherukuri, Amit Sureen, Taylor Infante, Nevetha Rajendran, Osvaldo Padilla, Sumit Gaur
Cureus. 2021;
[Pubmed]  [Google Scholar] [DOI]


Read this article